{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T21:25:54Z","timestamp":1790889954636,"version":"4.1.0"},"reference-count":21,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2012,5,1]],"date-time":"2012-05-01T00:00:00Z","timestamp":1335830400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,5,1]],"date-time":"2012-05-01T00:00:00Z","timestamp":1335830400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T00:00:00Z","timestamp":1670284800000},"content-version":"vor","delay-in-days":3871,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2012,5]]},"DOI":"10.1111\/j.1538-7836.2012.04667.x","type":"journal-article","created":{"date-parts":[[2012,2,21]],"date-time":"2012-02-21T12:32:09Z","timestamp":1329827529000},"page":"773-780","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":38,"title":["Phase\u00a0I, randomized, double\u2010blind, placebo\u2010controlled, single\u2010dose escalation study of the recombinant factor\u00a0VIIa variant BAY\u00a086\u20106150 in hemophilia"],"prefix":"10.1016","volume":"10","author":[{"given":"J.N.","family":"MAHLANGU","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.J.","family":"COETZEE","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"LAFFAN","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"WINDYGA","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.T.","family":"YEE","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"SCHROEDER","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"HAANING","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.E.","family":"SIEGEL","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"LEMM","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1111\/j.1538-7836.2012.04667.x_bb0010","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1046\/j.1365-2516.1998.00209.x","article-title":"A randomized, double\u2010blind comparison of two dosage levels of recombinant factor\u00a0VIIa in the treatment of joint, muscle and mucocutaneous haemorrhages in persons with haemophilia\u00a0A and B, with and without inhibitors. rFVIIa Study Group","volume":"4","author":"Lusher","year":"1998","journal-title":"Haemophilia"},{"key":"10.1111\/j.1538-7836.2012.04667.x_bb0015","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1111\/j.1365-2516.2005.01075.x","article-title":"Dose effect and efficacy of rFVIIa in the treatment of haemophilia patients with inhibitors: analysis from the Hemophilia and Thrombosis Research Society Registry","volume":"11","author":"Parameswaran","year":"2005","journal-title":"Haemophilia"},{"key":"10.1111\/j.1538-7836.2012.04667.x_bb0020","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1111\/j.1538-7836.2006.01772.x","article-title":"A prospective randomized trial of high and standard dosages of recombinant factor\u00a0VIIa for treatment of hemarthroses in hemophiliacs with inhibitors","volume":"4","author":"Santagostino","year":"2006","journal-title":"J Thromb Haemost"},{"key":"10.1111\/j.1538-7836.2012.04667.x_bb0025","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1046\/j.1538-7836.2003.00181.x","article-title":"How factor\u00a0VIIa works in hemophilia","volume":"1","author":"Butenas","year":"2003","journal-title":"J Thromb Haemost"},{"key":"10.1111\/j.1538-7836.2012.04667.x_bb0030","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1182\/blood.V99.3.923","article-title":"Mechanism of factor\u00a0VIIa\u2010dependent coagulation in hemophilia blood","volume":"99","author":"Butenas","year":"2002","journal-title":"Blood"},{"key":"10.1111\/j.1538-7836.2012.04667.x_bb0035","first-page":"14","article-title":"The action of high\u2010dose factor\u00a0VIIa (FVIIa) in a cell\u2010based model of hemostasis","volume":"49","author":"Hoffman","year":"2003","journal-title":"Dis Mon"},{"key":"10.1111\/j.1538-7836.2012.04667.x_bb0040","unstructured":"NovoSeven\u00ae (coagulation factor\u2003VIIa (recombinant)). Full Prescribing Information, Novo Nordisk A\/S, Bagsvaerd, Denmark, 2010."},{"key":"10.1111\/j.1538-7836.2012.04667.x_bb0045","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1055\/s-2000-8457","article-title":"Pharmacokinetics of recombinant activated factor\u00a0VII (rFVIIa)","volume":"26","author":"Erhardtsen","year":"2000","journal-title":"Semin Thromb Hemost"},{"key":"10.1111\/j.1538-7836.2012.04667.x_bb0050","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1016\/j.thromres.2010.01.025","article-title":"Platelet binding and activity of recombinant factor\u00a0VIIa","volume":"125","author":"Hoffman","year":"2010","journal-title":"Thromb Res"},{"key":"10.1111\/j.1538-7836.2012.04667.x_bb0055","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1055\/s-0037-1616518","article-title":"Structure and biology of tissue factor pathway inhibitor","volume":"86","author":"Bajaj","year":"2001","journal-title":"Thromb Haemost"},{"key":"10.1111\/j.1538-7836.2012.04667.x_bb0060","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1046\/j.1365-2141.1997.4463256.x","article-title":"Platelet activity of high\u2010dose factor\u00a0VIIa is independent of tissue factor","volume":"99","author":"Monroe","year":"1997","journal-title":"Br J Haematol"},{"key":"10.1111\/j.1538-7836.2012.04667.x_bb0065","doi-asserted-by":"crossref","first-page":"3858","DOI":"10.1182\/blood-2004-06-2223","article-title":"The use of recombinant factor\u00a0VIIa in the treatment of bleeding disorders","volume":"104","author":"Roberts","year":"2004","journal-title":"Blood"},{"key":"10.1111\/j.1538-7836.2012.04667.x_bb0070","doi-asserted-by":"crossref","first-page":"13583","DOI":"10.1073\/pnas.241339498","article-title":"Rational design of coagulation factor\u00a0VIIa variants with substantially increased intrinsic activity","volume":"98","author":"Persson","year":"2001","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1111\/j.1538-7836.2012.04667.x_bb0075","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1161\/01.ATV.0000257204.82396.2b","article-title":"A variant of recombinant factor\u00a0VIIa with enhanced procoagulant and antifibrinolytic activities in an in\u00a0vitro model of hemophilia","volume":"27","author":"Allen","year":"2007","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1111\/j.1538-7836.2012.04667.x_bb0080","doi-asserted-by":"crossref","first-page":"3615","DOI":"10.1182\/blood-2003-05-1369","article-title":"Improved hemostasis with superactive analogs of factor\u00a0VIIa in a mouse model of hemophilia\u00a0A","volume":"102","author":"Tranholm","year":"2003","journal-title":"Blood"},{"issue":"Suppl. 2","key":"10.1111\/j.1538-7836.2012.04667.x_bb0085","article-title":"Enhanced and prolonged efficacy of a novel recombinant FVIIa variant (BAY86\u20106150) for acute and prophylactic treatments in hemophilia\u00a0A (HemA) mice","volume":"7","author":"Liu","year":"2009","journal-title":"J Thromb Haemost"},{"key":"10.1111\/j.1538-7836.2012.04667.x_bb0090","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1002\/jps.20319","article-title":"Glycoengineering: the effect of glycosylation on the properties of therapeutic proteins","volume":"94","author":"Sinclair","year":"2005","journal-title":"J Pharm Sci"},{"issue":"Suppl. 2","key":"10.1111\/j.1538-7836.2012.04667.x_bb0095","article-title":"Binding to activated platelets and enhanced clotting properties of the recombinant FVIIa analogue Bay7","volume":"7","author":"Pan","year":"2009","journal-title":"J Thromb Haemost"},{"key":"10.1111\/j.1538-7836.2012.04667.x_bb0100","unstructured":"Common Terminology Criteria for Adverse Events, Version\u00a03.0. Available at: http:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/docs\/ctcae_index.pdf. Accessed 3 March 2011."},{"key":"10.1111\/j.1538-7836.2012.04667.x_bb0105","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1111\/j.1365-2516.2006.01306.x","article-title":"Treatment and outcome of acquired haemophilia\u00a0A with a standard conventional regimen in a cohort without associated conditions","volume":"12","author":"Ng","year":"2006","journal-title":"Haemophilia"},{"key":"10.1111\/j.1538-7836.2012.04667.x_bb0110","first-page":"98","article-title":"Long\u2010term follow\u2010up with regard to potential immunogenicity: clinical experience with NovoSeven (recombinant factor\u00a0VIIa)","volume":"26","author":"Nicolaisen","year":"1996","journal-title":"Haemostasis"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1538-7836.2012.04667.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783622062535?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783622062535?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1538-7836.2012.04667.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T02:59:35Z","timestamp":1761533975000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783622062535"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,5]]},"references-count":21,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2012,5]]}},"alternative-id":["S1538783622062535"],"URL":"https:\/\/doi.org\/10.1111\/j.1538-7836.2012.04667.x","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2012,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase\u00a0I, randomized, double\u2010blind, placebo\u2010controlled, single\u2010dose escalation study of the recombinant factor\u00a0VIIa variant BAY\u00a086\u20106150 in hemophilia","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1111\/j.1538-7836.2012.04667.x","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 International Society on Thrombosis and Haemostasis. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}